Akums Drugs & Pharmaceuticals reported a 29.5% year-on-year increase in net profit to Rs 86 crore for the third quarter, driven by robust demand across domestic formulations and contract manufacturing services. The earnings growth reflects improved operating leverage, efficient cost management and steady order inflows from branded pharmaceutical clients. As India’s contract development and manufacturing organization (CDMO) segment gains traction globally, Akums appears to be benefiting from scale efficiencies and diversified product capabilities.